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ABSTRACT 
The pharmacokinetic behavior of cyclosporine A (CyA), known as a potential immuno-
suppressive agent to prevent graft rejection in transplantation, was studied in patients with 
acute hepatitis and primary biliary cirrhosis (PBC). The ratios of blood concentration of total 
CyA (CyA and its metabolites), CyA, and CyA metabolites to dose/kg body weight, (t-CyA/dose, 
CyA/dose, and CyA-Met/dose, respectively) were significantly higher in patients with hepatitis 
than those in renal transplantation. In PBC patients these ratios showed a tendency to be 
smaller than those in renal transplantation, but were not significant. The ratio of CyA-Met/ 
CyA was higher in the patients with hepatitis and PBC than that in renal transplantation. 
It was highest in the patients with PBC. The ratio of CyA-Met/CyA was significantly 
increased with a decrease of liver functions evaluated by serum glutamic oxaloacetic transami-
nase (GOT), glutamic pyruvic transaminase (GPT), and total serum bilirubin (t-Bil). These 
results indicate that hepatic function affects the pharmacokinetic behavior of CyA and the 
increased ratio of CyA-Met/dose could be caused by a possible increased efflux of metabolites 
into the blood circulation due to impaired bile excretion. These results also indicate the impor-
tance of therapeutic drug monitoring (TDM) in the use of CyA with patients with hepatic 
dysfunction. 
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CyA has been used as a potential immuno-
suppressive agent to prevent graft rejection in 
transplantation including kidney, liver, lung, pan-
creas, and bone marrow transplants, and played 
an important role in the improvement of clinical 
results in transplantation6). Self-immunosensitive 
diseases like Bechet's syndrome are also indica-
tive for CyA3). However, CyA has serious nephro-
toxicity, neurotoxicity, and hepatotoxicity as 
adverse effects2,5). Therefore, monitoring of the 
blood concentration of CyA is indispensable in its 
clinical use. Correlations between concentration 
and immunosuppressive response have been 
reported in some studies4•8). However, the opti-
mal blood concentration of CyA in clinical use has 
not yet been established. Cy A is reported to be 
absorbed from the intestine, distributed widely, 
and then eliminated mainly through the bile and 
urine9). However, intestinal absorption of Cy A 
has been shown to be low and fluctuates accord-
ing to the individuall,B). Moreover, pharmacoki-
netic behavior is also affected by individual 
physiological conditions6). Thus, the optimal 
application of CyA is difficult to determine. Since 
Cy A is one of the drugs which enter the entero-
hepatic circulation, pharmacokinetic of CyA 
would be affected by hepatic function. In the 
present study, we studied the pharmacokinetic 
behavior of CyA in patients with liver dysfunc-
tion, acute hepatitis and PBC. 
MATERIALS AND METHODS 
TDM 
The trough blood concentrations of t-CyA and 
CyA at the steady state in patients to whom CyA 
had been orally administered were measured by 
the FPIA method using polyclonal or monoclonal 
antiserum, respectively11). From April 1991 to 
May 1994, the blood samples of 18 patients at 
Hiroshima University Hospital were proffered for 
TDM of CyA from the Department of Surgery II 
(Professor and Director, Kiyohiko Dohi, M.D., 
Ph.D.), the Department of Internal Medicine I 
(Professor and Director, Goro Kajiyama, M.D., 
Ph.D.), and the Department of Internal Medicine, 
Research Institute for Nuclear Medicine and Biol-
ogy (Professor and Director, Atsushi Kuramoto, 
M.D., Ph.D.) after receiving the informed consent 
in accordance with institutional guidelines. The 
number of patients with renal transplantation 
without liver dysfunction, with acute hepatitis, 
and with PBC were 13 (9 males and 4 females, 
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Table 1. Ratio of blood concentrations/dose of cyclosporine A and clinical data 
Renal Transplantation Acute hepatitis PBC 
(Ratio of blood concentrations*) 
t-CyA/dose 105.9 ± 99.0 239.5 ± 26.4 84.2 ± 21.9 
Cy A/dose 44.7 ± 33.l 92.7 ± 18.2 25.1 ± 9.3 
Cy-Met/dose 61.2 ± 66.2 146.8 ± 24.2 59.l ± 12.5 
Cy-Met/t-CyA 0.51 ± 0.12 0.61 ± 0.07 0.71 ± 0.04 
Cy-Met/Cy A 1.18 ± 0.3 1.74 ± 0.6 2.72 ± 0.5 
(Clinical data) 
GOT (u!l) 22 ± 8 117 ± 66 320 ± 149 
GPT(u/l) 33 ± 14 124 ± 75 282 ± 147 
t-Bil(mg/dl) 0.6 ± 0.2 10.5 ± 3.7 16.1 ± 14.6 
*: The abbreviations Cy A, Cy-Met, and t-CyA signify cyclosporine A, its metabolites, and Cy A plus Cy-Met, respectively. 
Cy A/dose, Cy-Met/dose, and t-CyA/dose signify ratio of their values (ng/ml) to dose(mg)/body weight (kg). 
33.8±11.0, 14 - 58 years old), 3 (1 male and 2 
females, 38.3±17.2, 15 - 56 years old), and 2 (2 
females, 2.2 and 31 years old), respectively. 
The blood concentration of CyA-Met was esti-
mated from the difference in concentration of 
CyA and t-CyA. 
Clinical data 
Clinical data of GOT, GPT, and t-Bil were 
obtained at the Clinical Laboratory Services, 
Hiroshima University Hospital (Professor and 
Director, Masayuki Kambe, M.D., Ph.D.), with an 
automatic analyzer (Model 7250, Hitachi Co. 
Ltd., Tokyo Japan). 
Statistical analysis 
The statistical analysis of the data was made 
by t test. A p value of< 0.05 was considered to 
be statistically significant. 
RESULTS 
Concentrations (ng/ml) of t-CyA, Cy A, and CyA-
Met in each patient group were normalized by 
dose(mg)/body weight (kg) and are summarized in 
Table 1 and Fig. 1. The ratios of blood concentra-
tion (ng/ml) to dose (mg/kg body weight), t-CyA/ 
dose, CyA/dose, and CyA-Met/dose, were 
239.5 ± 26.4, 92. 7±18.2, and 146.8 ± 24.2 (mg/ml), 
respectively, in acute hepatitis. Those in patients 
with renal transplantation were 105.9 ± 99.0, 
44. 7 ± 33 .1, and 61.2 ± 66.2, respectively. The 
ratios in acute hepatitis were significantly lower 
(p<0.05) than those in renal transplantation. 
Those in PBC were 84.2±21.9, 25.1±9.3, and 
59.1±12.5, respectively. In PBC, these values 
tended to be smaller than those in renal trans-
plantation, but were not significant. 
Fig. 2 illustrates the correlation of the ratio of 
Met/CyA to clinical data. The correlation coeffi-
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Fig. 1. Ratio of blood concentration (ng/ml) to dose 
(mg/kg body weight) of cyclosporine A and its 
metabolites in patients with renal transplantation, 
acute hepatitis, and primary biliary cirrhosis. 
cients (r) of the ratio to GOT, GPT, and t-Bil, 
were 0. 72, 0.38, and 0.67, respectively, and these 
values were significant (p<0.001). 
DISCUSSION 
As shown in Table 1, the clinical values of the 
patients with renal transplantation such as GOT, 
GPT, and t-Bil were within the normal range and 
those of the patients with acute hepatitis or PBC 
were higher than normal. The normalized value 
of t-CyA in the patients with acute hepatitis was 
found to be higher than that in the patients with 
renal transplantation or with PBC. The patients 
with PBC showed the lowest value of t-CyA. 
Because CyA is reported to be absorbed from the 
intestine with the aid of bile salts6), the absorp-
tion of Cy A from the intestine depends on the 
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This fact corresponds well with our results from 
the patients with acute hepatitis. As discussed 
above, the blood level of CyA will be affected by 
both the bile formation and the efflux from the 
liver cells. The obstruction of the bile flow was 
more severe in the patients with PBC than in the 
patients with acute hepatitis. In the patients 
with acute hepatitis, the bile salts were still 
available for the absorption of Cy A. The higher 
level of t-CyA/dose in the patients with acute 
hepatitis compared with those in renal trans-
plantation may be explained by a possible 
obstruction of biliary excretion of CyA and CyA-
Met. 
Because of the higher level of t-Bil, an almost 
complete obstruction of the bile flow is expected 
in patients with PBC. A complete obstruction of 
the bile flow will cause impairment of the intesti-
nal absorption of CyA, because CyA is absorbed 
by the intestine with the aid of bile salts. The 
lower blood of t-CyA/dose in the patients with 
PBC may be mainly attributable to an impair-
ment of intestinal absorption. The similar values 
of CyA-Met/CyA in the three patient groups 
(Table 1) suggest that CyA is still metabolized by 
the liver in spite of liver dysfunction in the 
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Fig. 2. Correlation of the ratio of metabolites/ 
cyclosporine A to GOT, GPT, and t-Bil. 
degree of obstruction of the bile flow. Further, the 
concentration of t-CyA in the blood depends on 
both the absorbed amount of CyA and the efflux 
of CyA and CyA-Met into the blood circulation 
from the liver cells. In the case of acute hepatitis 
or PBC, the bile flow is obstructed to some extent 
depending on the condition of the patients. In 
such patients, the blood level of CyA and CyA-
Met would tend to be increased by the excessive 
efflux from the liver cells. It has been reported 
that an acute ligation of the bile duct increased 
the blood CyA concentration by two to sixfold10). 
The value of CyA-Met/CyA correlates with clini-
cal data as shown Fig. 2. These findings suggest 
that an excessive efflux of CyA and CyA-Met into 
the blood circulation from the liver is related to 
the degree of injury of the hepatocytes, which 
caused the obstruction of bile flow. 
In the present study, we demonstrated that the 
pharmacokinetic behavior of Cy A was affected by 
liver dysfunction, especially obstruction of the 
bile flow and the efflux of CyA and CyA-Met into 
the blood circulation from the hepatocytes. These 
findings strongly support that TDM is indispens-
able to therapy with CyA especially in patients 
with liver dysfunction. 
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